Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Bluejay Diagnostics (BJDX) Gains from Sales and Divestitures (2023 - 2025)

Bluejay Diagnostics' Gains from Sales and Divestitures history spans 1 years, with the latest figure at $19484.0 for Q4 2023.

On a quarterly basis, Gains from Sales and Divestitures changed N/A to $19484.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $19484.0, a N/A change, with the full-year FY2023 number at $19484.0, changed N/A from a year prior.
Gains from Sales and Divestitures hit $19484.0 in Q4 2023 for Bluejay Diagnostics, roughly flat from $19484.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for BJDX hit a ceiling of $374680.0 in Q1 2023 and a floor of $19484.0 in Q2 2023.